Stock Ratings / Health Care / CDRE / forecast

ENOV (44) ESTA (30) AVR (23) SMTI (55) ⌘ Pro Terminal →

Cadre Holdings Inc. (CDRE) 12-Month Stock Forecast & Price Target Cone

$31.10 +3.81% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $31.25

Cadre Holdings Inc. (CDRE) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.33B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CDRE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CDRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Cadre Holdings Inc. (NYSE: CDRE) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $31.10 (+3.81% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, CDRE ranks #161 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CDRE compare to ENOV and ESTA in the Health Care sector?

▼

Within the Health Care sector (Industrial Specialties), CDRE carries a Roarable C (62/100 RQD), trailing P/E of 30.2x, gross margin of 42.5%, and ROIC of 11.0%. By comparison, ENOV (Enovis Corporation) holds a D grade (44/100 RQD, P/E N/A, ROIC -32.7%, cap $1.32B) and ESTA (Establishment Labs Holdings Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -15.8%, cap $2.04B). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CDRE?

▼

Per CDRE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001860543), Cadre Holdings Inc. generated $610.3M in revenue (+7.5% YoY), $44.1M in net income, and $56.8M in free cash flow against $770.0M in total assets and $291.0M in total debt. Key quantitative strengths: Strong cash generator (43% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $31.26 (+0.50%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 9.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CDRE)Realized 20D OHLCV Swing Band: ±8.9%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY CDRE SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 9.3% FCF Margin ($56.8M FCF) & 42.5% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (24% of score)

Altman Z-Score 3.32 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)

Macro rate sensitivity & RSI-14 (68.2) create a -13 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$25.84+4.8% Next Q

Q2 (-2Q)

Grade C$27.07+13.2% Next Q

Q3 (-1Q)

Grade C$30.63+1.5% Next Q

Current

Grade C$31.10+0.7% Hist 90D α

Trajectory: C- (54) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CDRE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, CDRE faces multiple-compression risk if 30.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 40.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($27.90) or 200D SMA ($32.16) invalidates the momentum regime and cuts Target Base ($31.66) toward Bear Floor ($24.69).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CDRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CDRE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CDRE Position Size: $10,000

Shares at $31.10: 321.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $24.69

$7,939

$-2,061 (-20.6%)

12M Consensus BaseTarget $31.66

$10,180

+$180 (+1.8%)

12M Bull Case BreakoutTarget $51.20

$16,463

+$6,463 (+64.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$33	74%	A
Goldman SachsSector Coverage Lead	BUY	$48	69%	B
JP MorganUS Large-Cap Research	HOLD	$28	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CDRE Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CDRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.85%📐 HORIZONTAL RANGE

2026-11-02O $29.96H $31.10L $29.96C $31.10VOL 433.1K

RES: $43.00SUP: $23.01SMA50: $27.90SMA200: $32.16

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CDRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CDRE Butterfly Map → + Track CDRE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

23.3%/yr Implied 5Y Growth

vs. +7.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CDRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CDRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CDRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CDRE)

Health Care Rank #161 of 1016 ⚔️ ENOV vs CDRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CDRE vs. ENOV, ESTA, AVR, SMTI)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cadre Holdings Inc. (CDRE) ranks #161 by composite RQD confidence (62/100, grade C) and #323 by equity capitalization ($1.33B). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. CDRE currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CDRE ACTIVE Cadre Holdings Inc.	C	62/100	30.2x	42.5%	11.0%	+3.81%	$1.33B	Benchmark Subject
ENOV Enovis Corporation	D	44/100	—	59.8%	-32.7%	+4.11%	$1.32B	/enov-vs-cdre →
ESTA Establishment Labs Holdings Inc.	E	30/100	—	69.3%	-15.8%	-0.81%	$2.04B	/esta-vs-cdre →
AVR Anteris Technologies Global Corp.	E	23/100	—	70.3%	-35.0%	+5.25%	$625.9M	/avr-vs-cdre →
SMTI Sanara MedTech Inc.	D+	55/100	8.1x	92.7%	16.3%	+0.11%	$302.4M	/smti-vs-cdre →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001860543

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cadre Holdings Inc. (CDRE) reported GAAP revenue of $610.3M (+7.5% vs. FY2024 revenue of $567.6M , and +26.5% cumulative change since FY2023) , GAAP net income of $44.1M, operating cash flow of $63.7M, and free cash flow of $56.8M (+117.7% YoY). On the balance sheet, CDRE closed FY2025 with $770.0M in total assets against $291.0M in total debt (Altman Z-Score: 3.32, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$610.3M	$44.1M	$63.7M	$56.8M	$770.0M	$291.0M
FY2024 (FY)	2024-12-31	$567.6M	$36.1M	$31.8M	$26.1M	$652.7M	$211.8M
FY2023 (FY)	2023-12-31	$482.5M	$38.6M	$73.2M	$73.2M	—	—

3. CDRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CDRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CDRE compare to ENOV and ESTA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CDRE?

Where is CDRE trading relative to its 50-day, 200-day, and 52-week technical levels?

CDRE last traded at $31.10 (+3.81% on volume of 433,055 shares), positioning the stock +11.47% above its 50-day simple moving average ($27.90) and -3.30% below its 200-day simple moving average ($32.16). Across its 52-week range of $24.07 to $48.76, CDRE sits at the 28.5% percentile with a 14-day RSI of 68.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.9% ($28.33 to $33.87).

CDRE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CDRE's 12-month stock price target?

Cadre Holdings Inc. (CDRE) carries a 12-month consensus base price target of $31.66 (+1.8% from $31.10), with a bull-case target of $51.2 and a bear-case floor of $24.69.